Mar 9, 2002|
Vaccines Market: Needs a booster
The global vaccine business has experienced considerable growth and innovation over the past decade with preventive healthcare gaining importance. As explained in our earlier report on vaccines, these drugs are basically antigenic preparation used to stimulate the production of antibodies and procure immunity from one or several diseases. Though the segment is logging attractive growth rates, it faces problems in terms of getting enough R&D attention.
The global vaccine industry at US$ 7 bn is miniscule in terms of total pharma market. Vaccines currently account for only 2% of the global pharmaceutical product sales with few players dominating the industry. The concentration could be explained by the fact that it requires massive R&D investments to develop mass immunisation vaccines.
Further, in recent years, most of the big players have introduced combination vaccines, which have made specific vaccines redundant. For example, Glaxo, with a 25% market share in vaccines dominates this business due to its technological expertise in producing combination vaccines. While the company's combination vaccine sales recorded a growth of 26%, individual vaccines sales dropped 10%.
GSK- Vaccine Product Portfolio
||Hepatitis A Vaccine.
||Hepatitis B vaccine.
||Combinational vaccine for Hepatitis A and B
||Combinational vaccine for Hepatitis B and DTP
||Combinational vaccine for Tetanus and Diptheria
In recent years, advances in biotechnology such as genomics, recombinant DNA and peptides have provided impetus for new vaccine development. However, the demand for vaccines have remained skewed towards developed nations, which account for more than 2/3rd of the total consumption. On the other hand, there is vast untapped potential in developing countries where the demand is slow due to illiteracy. Though health ministries of third world countries have made significant progress by various immunisation programmes, success has been marginal. Again the demand is skewed towards pediatric segment and the adult vaccines segment is largely untapped due to lack of education.
Estimates suggest that the vaccines industry is in for some exciting times with a CAGR of 11-13% targeted for the next ten years. However, the primary area of concern for the industry is that the research in this segment is not very forthcoming. This is due to the fact that unlike pharmaceutical drugs, commercial success is not assured even after a successful discovery, as the response is not very predictable. In this scenario, a key challenge for the industry is to maintain a healthy environment for research and development.
More Views on News
Aug 14, 2017
A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.
Aug 14, 2017
GST impact coupled with price erosion in US leads to lower profits for the quarter.
Aug 8, 2017
Profits plunge due to higher raw material costs.
Jun 16, 2017
Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
Jun 23, 2017
Net Profit lower due to exceptional items in the previous year.
More Views on News
Aug 17, 2017
A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.
Aug 10, 2017
Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 10, 2017
Bitcoin hits an all-time high, is there more upside left?
Aug 16, 2017
Ensure your financial Independence, and pledge to start the journey towards financial freedom today!
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407